TRYPU - Overview: Tryptophan, Random, Urine

Aiding in the screening and monitoring of Hartnup disease

PDETS - Overview: Phosphodiesterase 10A (PDE10A) IgG, Tissue Immunofluorescence Titer, Serum

Reporting an end titer result from phosphodiesterase 10A (PDE10A) in serum specimens Evaluation of autoimmune/paraneoplastic neurological syndromes among patients presenting with movement disorders and encephalopathy

PDEIC - Overview: Phosphodiesterase 10A (PDE10A) IgG, Tissue Immunofluorescence, Spinal Fluid

Detecting phosphodiesterase 10A (PDE10A)-IgG in cerebrospinal fluid specimens Evaluation of autoimmune/paraneoplastic neurological syndromes among patients presenting with movement disorders and encephalopathy

PDETC - Overview: Phosphodiesterase 10A (PDE10A) IgG, Tissue Immunofluorescence Titer, Spinal Fluid

Reporting an end titer result from phosphodiesterase 10A (PDE10A) in spinal fluid specimens Evaluation of autoimmune/paraneoplastic neurological syndromes among patients presenting with movement disorders and encephalopathy

PDEIS - Overview: Phosphodiesterase 10A (PDE10A) IgG, Tissue Immunofluorescence, Serum

Detecting phosphodiesterase 10A (PDE10A)-IgG in serum specimens Evaluation of autoimmune/paraneoplastic neurological syndromes among patients presenting with movement disorders and encephalopathy

KIPM - Overview: Ki-67(MIB-1), Pulmonary, Quantitative Immunohistochemistry, Manual

Determining proliferation of tumor cells in paraffin-embedded tissue blocks from patients diagnosed with carcinoid or atypical carcinoid of the lung including metastases, using a manual method

NEGCT - Overview: Negative Control, Technical Component Only

Qualitative detection of protein expression within cells in paraffin-embedded tissues

CRETR - Overview: Creatinine, Random, Urine

Normalization of urinary analytes to account for the variation in urinary concentrations between individuals when using random urine collections

EPC2 - Overview: Epilepsy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid

Investigating new onset cryptogenic epilepsy with incomplete seizure control and duration of fewer than 2 years using spinal fluid specimens Investigating new onset cryptogenic epilepsy plus 1 or more of the following...

EPS2 - Overview: Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum

Investigating new onset cryptogenic epilepsy with incomplete seizure control and duration of less than 2 years, using serum specimens Investigating new onset cryptogenic epilepsy plus 1 or more of the following accompaniments: -Psychiatric...